4.6 Article

Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST)

期刊

AMERICAN JOURNAL OF OPHTHALMOLOGY
卷 160, 期 6, 页码 1133-1141

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2015.09.017

关键词

-

资金

  1. NATIONAL EYE INSTITUTE (BETHESDA, MARYLAND) [U10EY014655, U10EY014660, U10EY014656]
  2. Bausch & Lomb (Rochester, New York)
  3. Research to Prevent Blindness (New York, New York)
  4. Paul and Evanina Mackall Foundation (New York, New York)
  5. Lois Pope Life Foundation (New York, New York)
  6. Allergan

向作者/读者索取更多资源

PURPOSE: To identify factors associated with best-corrected visual acuity (BCVA) presentation and 2-year outcome in 479 intermediate, posterior, and panuveitic eyes. DESIGN: Cohort study using randomized controlled trial data. METHODS: Multicenter Uveitis Steroid Treatment (MUST) Trial masked BCVA measurements at baseline and at 2 years follow-up used gold-standard methods. Twenty-three clinical centers documented characteristics per protocol, which were evaluated as potential predictive factors for baseline BCVA and 2-year change in BCVA. RESULTS: Baseline factors significantly associated with reduced BCVA included age >= 50 vs < 50 years; posterior vs intermediate uveitis; uveitis duration > 10 vs < 6 years; anterior chamber (AC) flare > grade 0; cataract; macular thickening; and exudative retinal detachment. Over 2 years, eyes better than 20/50 and 20/50 or worse at baseline improved, on average, by 1 letter (P = .52) and 10 letters (P < .001), respectively. Both treatment groups and all sites of uveitis improved similarly. Factors associated with improved BCVA included resolution of active AC cells, resolution of macular thickening, and cataract surgery in an initially cataractous eye. Factors associated with worsening BCVA included longer duration of uveitis (6-10 or > 10 vs < 6 years), incident AC flare, cataract at both baseline and follow-up, pseudophakia at baseline, persistence or incidence of vitreous haze, and incidence of macular thickening. CONCLUSIONS: Intermediate, posterior, and panuveitis have a similarly favorable prognosis with both systemic. and fluocinolone acetonide implant treatment. Eyes with more prolonged/severe inflammatory damage and/or inflammatory findings initially or during follow-up have a worse visual acuity prognosis. The results indicate the value of implementing best practices in managing inflammation. (C) 2015 by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据